| [1] |
Ageno W,Gallus AS,Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest, 2012, 141(2 Suppl):e44S-e88S.
|
| [2] |
Kreutz R,Haas S,Holberg G, et al. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions[J]. Br J Clin Pharmacol, 2016, 81(4):724-734.
|
| [3] |
Bayer Pharma AG. Xarelto®(rivaroxaban) Summary of Product Characteristics. 2015. http://www.ema.europa.eudocsen_GBdocument_libraryEPAR_‐_Product_Informationhuman000944WC500057108
|
| [4] |
Brandão GM,Sobreira ML,Malgor RD, et al. Recanalization rates after acute deep vein thrombosis: a single-center experience using a newly proposed vein diameter variation index[J].Ann Vasc Surg, 2014, 28(7):1751-1760.
|
| [5] |
中华医学会骨科学分会.中国骨科大手术静脉血栓栓塞症预防指南[J].中华骨科杂志，2016，36（2）：65-71.
|
| [6] |
Turpie AG,Lassen MR,Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial[J]. Lancet, 2009, 373(9676):1673-1680.
|
| [7] |
Eriksson BI,Borris LC,Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J]. N Engl J Med, 2008, 358(26):2765-2775.
|
| [8] |
Granero J,Díaz de Rada P,Lozano LM, et al. [Rivaroxaban versus standard of care in venous thromboembolism prevention following hip or knee arthroplasty in daily clinical practice (Spanish data from the international study XAMOS)][J]. Rev Esp Cir Ortop Traumatol, 2016, 60(1):44-52.
|
| [9] |
Pathak R,Giri S,Karmacharya P, et al. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients[J]. Blood Coagul Fibrinolysis, 2015, 26(8):934-939.
|
| [10] |
Zhang YM,Jiang X,Sun YS. Effect of rivaroxaban on preventing deep vein thrombosis in aged diabetics with femoral neck fractures after hip replacement[J]. Biosci Rep, 2017, 37(3). pii:BSR20170289.
|
| [11] |
Kim SM,Moon YW,Lim SJ, et al. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty[J]. Thromb Haemost, 2016, 115(3):600-607.
|
| [12] |
Loganathan L,Hua A,Patel S, et al. Efficacy and safety of rivaroxaban thromboprophylaxis after arthroplasty of the hip or knee: retrospective cohort study[J].Ann R Coll Surg Engl, 2016, 98(7):507-515.
|
| [13] |
中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南（第3版）[J].中华普通外科杂志, 2017，32（9）：807-812.
|
| [14] |
Konstantinides SV,Torbicki A,Agnelli G, et al. Corrigendum to: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism[J]. Eur Heart J, 2015, 36(39):2642.
|
| [15] |
Landman GW,Gans RO. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med, 2011, 364(12): 1178.
|
| [16] |
Gaertner S,Cordeanu EM,Nouri S, et al. Rivaroxaban versus standard anticoagulation for symptomatic venousthromboembolism (REMOTEV observational study): Analysis of 6-month outcomes[J]. Int J Cardiol, 2017, 226:103-109.
|
| [17] |
Brighton TA,Eikelboom JW,Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism[J]. N Engl J Med, 2012, 367(21):1979-1987.
|
| [18] |
Toth PP. Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era[J]. Vasc Health Risk Manag, 2016, 12: 23-34.
|
| [19] |
Weitz JI,Lensing AWA,Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism[J].N Engl J Med, 2017, 376(13):1211-1222.
|
| [20] |
边明艳，卜丽，孟晓丹，等.高龄患者长期服用利伐沙班抗凝治疗临床安全性观察[J].中华实用诊断与治疗杂志，2016，30（12）：1247-1248.
|
| [21] |
Patel MR,Mahaffey KW,Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med, 2011, 365(10):883-891.
|
| [22] |
杨新春.《2016年欧洲心脏病学会心房颤动管理指南》解读[J].中国介入心脏病学杂志，2016，24（11）：623-628.
|
| [23] |
Halperin JL,Hankey GJ,Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)[J].Circulation, 2014, 130(2):138-146.
|
| [24] |
赵瑞骅，李小明，马英，等.高龄老年非瓣膜性心房颤动患者应用新型口服抗凝药抗凝治疗有效性及安全性评价研究[J].中国药物与临床，2017，17（6）：805-809.
|
| [25] |
刘晓红，杜雷，杨晨，等.利伐沙班抗凝治疗老年非瓣膜性心房颤动患者的效果[J].中国临床保健杂志，2016，19（4）：397-399.
|
| [26] |
Pokorney SD,Piccini JP,Stevens SR, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF[J]. J Am Heart Assoc, 2016, 5(3):e002197.
|
| [27] |
Mega JL,Braunwald E,Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome[J].N Engl J Med, 2012, 366(1):9-19.
|
| [28] |
王冬，王岩.小剂量利伐沙班治疗不稳定型心绞痛的临床疗效观察[J].保健医学研究与实践，2014，11（6）：46-47.
|
| [29] |
杨燕.不同剂量的利伐沙班及护理干预用于急性冠脉综合征73例对比研究[J].中国药业，2014，23（12）：34-36.
|
| [30] |
刘炜，滕旭，张颖.利伐沙班治疗非ST段抬高急性冠脉综合征的疗效观察[J].中国民康医学，2014，26（5）：33-35.
|
| [31] |
胡军，胡名松，曾慰，等.利伐沙班对急性冠脉综合症患者炎症相关因子的影响[J].中南医学科学杂志，2014，42（4）：370-372.
|
| [32] |
刘晓燕.利伐沙班治疗高龄急性冠脉综合征的临床疗效观察[J].临床合理用药杂志，2017，10（11A）：53-54.
|
| [33] |
Paikin JS,Wright DS,Crowther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents[J]. Circulation, 2010, 121(18):2067-2070.
|
| [34] |
Gibson CM,Mehran R,Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI[J]. N Engl J Med, 2016, 375(25):2423-2434.
|
| [35] |
Zannad F,Stough WG,Regnault V, et al. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges[J]. Int J Cardiol, 2013, 167(5):1772-1782.
|
| [36] |
Zannad F,Greenberg B,Cleland JG, et al. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial[J]. Eur J Heart Fail, 2015, 17(7):735-742.
|
| [37] |
Eikelboom JW,Connolly SJ,Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med, 2017, 377(14):1319-1330.
|
| [38] |
Anand SS,Bosch J,Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2017, doi: 10.1016/S0140-6736(17)32409-1.[Epub ahead of print] |